[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2014012945A - Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). - Google Patents

Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Info

Publication number
MX2014012945A
MX2014012945A MX2014012945A MX2014012945A MX2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A
Authority
MX
Mexico
Prior art keywords
aminopyrimidine derivatives
lrrk2
pyrazole
modulators
lrrk2 modulators
Prior art date
Application number
MX2014012945A
Other languages
English (en)
Other versions
MX363118B (es
Inventor
Huifen Chen
Charles Baker-Glenn
Mark Chambers
Bryan K Chan
Anthony Estrada
Daniel Jon Burdick
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014012945A publication Critical patent/MX2014012945A/es
Publication of MX363118B publication Critical patent/MX363118B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de pirazol que son moduladores de LRRK2, con métodos para elaborar los compuestos, y con métodos para usar los compuestos para el tratamiento de enfermedades asociadas con el receptor LRRK2, tal como la enfermedad de Parkinson.
MX2014012945A 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). MX363118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642019P 2012-05-03 2012-05-03
PCT/EP2013/058939 WO2013164321A1 (en) 2012-05-03 2013-04-30 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (2)

Publication Number Publication Date
MX2014012945A true MX2014012945A (es) 2015-02-10
MX363118B MX363118B (es) 2019-03-11

Family

ID=48325675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012945A MX363118B (es) 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Country Status (11)

Country Link
US (1) US9212173B2 (es)
EP (1) EP2844652B1 (es)
JP (1) JP6218808B2 (es)
KR (1) KR102091894B1 (es)
CN (2) CN106220615A (es)
BR (1) BR112014026952B1 (es)
CA (1) CA2870049C (es)
HK (1) HK1200820A1 (es)
MX (1) MX363118B (es)
RU (1) RU2637947C2 (es)
WO (1) WO2013164321A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6211061B2 (ja) * 2012-05-03 2017-10-11 ジェネンテック， インコーポレイテッド パーキンソン病の処置における使用のためのｌｒｒｋ２モジュレーターとしてのピラゾールアミノピリミジン誘導体
GEP201706620B (en) 2012-06-29 2017-02-10 Pfizer NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
ES2812605T3 (es) 2013-12-20 2021-03-17 Signal Pharm Llc Compuestos de diaminopirimidilo sustituidos, composiciones de los mismos y procedimientos de tratamiento con ellos
RU2016134751A (ru) 2014-01-29 2018-03-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
KR20160106622A (ko) 2014-01-29 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
JP2017521465A (ja) * 2014-07-24 2017-08-03 バイエル・ファルマ・アクティエンゲゼルシャフト グルコース輸送阻害剤
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
CN108934162A (zh) * 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
PE20190395A1 (es) * 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
EP3645518B1 (en) * 2017-06-30 2021-05-19 Amgen Inc. Synthesis of omecamtiv mecarbil
ES2975319T3 (es) * 2017-11-21 2024-07-04 Denali Therapeutics Inc Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
ES2975958T3 (es) * 2017-12-20 2024-07-18 Denali Therapeutics Inc Procedimiento para la preparación de compuestos de pirimidinil-4-aminopirazol
KR102501982B1 (ko) 2018-02-14 2023-02-20 오사카 유키가가쿠고교 가부시키가이샤 내열성과 용이 박리성의 경화수지막을 형성하는 경화성 수지 조성물 및 그의 제조 방법
WO2019160037A1 (ja) * 2018-02-14 2019-08-22 国立大学法人 東京大学 酸ハロゲン化物による化合物の製造方法
IL281765B2 (en) * 2018-09-25 2024-04-01 Cardurion Pharmaceuticals Inc Aminopyrimidine compound
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
CN111718332B (zh) * 2019-03-19 2021-08-17 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
EP3980412A4 (en) * 2019-06-06 2023-05-31 Merck Sharp & Dohme LLC INDAZOLE 5-, 6-DISUBSTITUTED, 1-PYRAZOLYL DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP4232040A1 (en) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2024097394A1 (en) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
TW202434571A (zh) 2022-11-22 2024-09-01 美商戴納立製藥公司 嘧啶胺基吡唑化合物之製備方法及中間物
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
PT1317448E (pt) * 2000-09-15 2005-08-31 Vertex Pharma Compostos de pirazole uteis como inibidores de proteina-quinase
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2010144468A1 (en) * 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
PT2576541T (pt) * 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CA2809836C (en) * 2010-09-01 2019-01-15 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
RS59106B1 (sr) * 2010-11-10 2019-09-30 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
US8637537B2 (en) * 2011-08-25 2014-01-28 Genentech, Inc. Serine/threonine kinase inhibitors
US8669251B2 (en) * 2011-11-03 2014-03-11 Genentech, Inc. 8-fluorophthalazin-1(2H)-one compounds
PT2820009T (pt) * 2012-03-01 2018-04-12 Array Biopharma Inc Inibidores de serina/treonina quinases
MX2015003513A (es) * 2012-09-26 2015-07-17 Hoffmann La Roche Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion.
MA38624A1 (fr) * 2013-05-01 2017-02-28 Hoffmann La Roche Composés bihétéroaryle et leurs utilisations

Also Published As

Publication number Publication date
CN104271569A (zh) 2015-01-07
RU2014147381A (ru) 2016-06-27
KR102091894B1 (ko) 2020-03-20
JP6218808B2 (ja) 2017-10-25
BR112014026952B1 (pt) 2022-03-15
WO2013164321A1 (en) 2013-11-07
EP2844652B1 (en) 2019-03-13
CN104271569B (zh) 2016-08-24
CN106220615A (zh) 2016-12-14
US20150051238A1 (en) 2015-02-19
CA2870049C (en) 2020-12-29
CA2870049A1 (en) 2013-11-07
KR20150016532A (ko) 2015-02-12
BR112014026952A2 (pt) 2017-06-27
EP2844652A1 (en) 2015-03-11
BR112014026952A8 (pt) 2021-06-15
HK1200820A1 (zh) 2015-08-14
US9212173B2 (en) 2015-12-15
RU2637947C2 (ru) 2017-12-08
MX363118B (es) 2019-03-11
JP2015515966A (ja) 2015-06-04

Similar Documents

Publication Publication Date Title
MX2014012945A (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
PH12013500880A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
NZ737399A (en) Ccr2 modulators
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12012502373A1 (en) Aminopyrimidine derivatives as lrrk2 modulators
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
HK1195309A1 (zh) 作為激酶 調節劑用於治療帕金森病的 -苯基氨基嘧啶衍生物
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
SG194718A1 (en) Novel compounds as modulators of protein kinases
MX2015000129A (es) Derivados de pirimidin pirazolilo.
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
EP4450130A3 (en) Formulations of enzalutamide
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
RS55370B1 (sr) 2-(fenil ili pirid-3-il)aminopirimidinski derivati kao modulatori lrrk2 kinaze za lečenje parkinsonove bolesti
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).